Video Experimental Relacionado
Updated: Aug 18, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Profilaxis de la ictericia neonatal con tratamiento maternal con antipirinas
Lancet (London, England)
|February 10, 1979
Resumen
Las madres tratadas con antipirina (fenazona) durante el embarazo mostraron una reducción significativa en la ictericia neonatal. Este tratamiento redujo los niveles de bilirrubina plasmática neonatal en un 44% en el cuarto día de vida.
Área de la Ciencia:
- Medicina Neonatal La medicina neonatal es una especialidad de la medicina neonatal.
- Farmacología Farmacología.
Sus antecedentes:
- La ictericia neonatal es una afección común que afecta a los recién nacidos.
- Las medidas profilácticas efectivas son cruciales para prevenir la hiperbilirubinemia grave.
Objetivo del estudio:
- Evaluar la eficacia de la antipirina (fenazona) en la prevención de la ictericia neonatal.
Principales métodos:
- Un ensayo controlado aleatorio en el que participaron 48 mujeres embarazadas.
- El tratamiento materno con antipirina debe iniciarse a partir de la semana 38 de gestación.
Principales resultados:
- El tratamiento redujo significativamente las concentraciones plasmáticas neonatales de bilirrubina.
- Se observó una reducción promedio del 44% en la bilirrubina plasmática al cuarto día después del parto.
Conclusiones:
- La antipirina (fenazona) se muestra prometedora como tratamiento profiláctico para la ictericia neonatal.
- Además, se necesitan ensayos más amplios para confirmar estos hallazgos.
Videos de Conceptos Relacionados
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:25Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...